Quince Therapeutics, Inc. (QNCX) has 13 open-market insider trades by 6 insiders since 2023. The most active filer is David Lamond, Director.
| Name | Title | Tier | Trades | Value | Last Trade |
|---|---|---|---|---|---|
| David Lamond | Dir | — | 5 | $1.0M | 2023-12-14 |
| Dirk Thye | CEO | — | 3 | $371K | 2025-12-10 |
| Brendan Hannah | — | — | 2 | $199K | 2025-12-05 |
| Luca Benatti | Dir | — | 1 | $174K | 2025-12-26 |
| Charles S. Ryan | Pres | — | 1 | $31K | 2025-06-18 |
| Margaret McLoughlin | Dir | — | 1 | $10K | 2023-08-08 |
| Insider | Title | Type | Value | Date |
|---|---|---|---|---|
| Luca Benatti | Director | Sell | $174K | 2025-12-26 |
| Dirk Thye | CEO | Buy | $161K | 2024-08-29 |
| Charles S. Ryan | President | Buy | $31K | 2024-08-20 |
| Brendan Hannah | CHIEF BUSINESS OFFICER AND COO | Buy | $24K | 2024-08-19 |
| David Lamond | Director | Buy | $69K | 2023-12-12 |
| David Lamond | Director | Buy | $58K | 2023-12-05 |
Companies that share insiders with QNCX, and sector peers with recent insider buying. Related by who files, not by how the stocks move.
| David Lamond | Director | Buy | $41K | 2023-11-29 |
| David Lamond | Director | Buy | $216K | 2023-08-30 |
| David Lamond | Director | Buy | $620K | 2023-08-15 |
| Dirk Thye | CEO | Buy | $111K | 2023-08-10 |
| Brendan Hannah | — | Buy | $175K | 2023-08-08 |
| Margaret McLoughlin | Director | Buy | $10K | 2023-08-08 |
| Dirk Thye | CEO | Buy | $99K | 2023-08-08 |
| Ted Monohon | Chief Accounting Officer & VP | Sell | $2K | 2023-03-06 |